TNF-related apoptosis-inducing ligand and cardiovascular disease in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 33, Issue 4, 2015, Pages 491-497

  Dessein, Patrick H ^a   Lopez Mejias, Raquel ^b   Ubilla, Begona ^b   Genre, Fernanda ^b   Corrales, Alfonso ^b   Hernández, Jose L ^b   Ferraz Amaro, Ivan ^c   Tsang, Linda ^a   Pina, Trinitario ^a   Llorca, Javier ^d   Blanco, Ricardo ^b   Gonzalez Juanatey, Carlos ^e   González Gay, Miguel A ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^d UNIVERSITY OF CANTABRIA   (Spain)

^e Hospital Lucus Augusti   (Spain)

Author keywords

C reactive protein; Cardiovascular disease; Rheumatoid arthritis; TNF related apoptosis inducing ligand

Indexed keywords

OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; AGED; BLOOD; METABOLISM; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PERIPHERAL ARTERIAL DISEASE; REGRESSION ANALYSIS; SPAIN; STROKE;

AGED; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; OSTEOPROTEGERIN; PERIPHERAL ARTERIAL DISEASE; REGRESSION ANALYSIS; RISK FACTORS; SPAIN; STROKE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84939474960     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. BERNARDI S, MILANI D, FABRIS B, SECCHIERO P, ZAULI G: TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases. Curr Drug Targets 2014; 13: 1215-21.
2. BROMBO G, VOLPATO P, SECCHIERO P et al.: Association of soluble tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with central obesity and low-density lipoprotein cholesterol. PLoS ONE 2013; 8: e58255.
3. DI PIETRO R, ZAULI G: Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L. J Cell Physiol 2004; 201: 331-40.
4. WILEY SR, SCHOOLEY K, SMOLAK PJ et al.: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-82.
5. AUDO R, COMBE B, HAHNE R, MOREL J: Two different directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis. Cytokine 2013; 63: 81-90.
6. AUDO R, CALMON-HAMATY F, BAETEN D et al.: Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis. Arthritis Rheum 2011; 63: 904-13.
7. SECCHIERO P, CORALLINI F, CASTELLINO F et al.: Baseline serum concentrations of TRAIL in early rheumatoid arthritis: relationship with response to disease-modifying drugs. J Rheumatol 2010; 37: 1461-6.
8. MORALES-LARA MJ, CANETE JD, TORRES-MORENO D, HERNANDZ MVM, CELIS R, GARCIA R: Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 2012; 79: 591-6.
9. SOLOMON DH, KARLSON EW, RIMM EB et al.: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-7.
10. AVINA-ZUBIETA JA, CHOI HK, SADATSAFAVI M, ETIMINAN M, ESDAILE JM, LACCAILLE D: Risk of cardiovascular mortality in rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-7.
11. LINDHARDSEN J, AHLEHOFF O, GISLAHSON GH et al.: Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study. BMJ 2012; 344: e1257.
12. STAMATEMOPOULOS KS, KITAS GD, PAPA-MICHAEL CM et al.: Subclinical peripheral arterial disease in rheumatoid arthritis. Atherosclerosis 2010; 212: 305-9.
13. NICOLA PJ, MARADIT-KREMERS H, ROGER VL et al.: The risk of congestive heart failure in rheumatoid arthritis. Arthritis Rheum 2005; 52: 412-20.
14. DESSEIN PH, NORTON GR, WOODIWISS AJ, JOFFE BI, WOLFE F: Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 2007; 34: 943-51.
15. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, MARTIN J: Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35: 8-17.
16. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, LOPEZ-DIAZ MJ et al.: HLA-DRB1 and persistent inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 15: 125-32.
17. RODRIGUEZ-RODRIGUEZ L, GONZALEZ-JUANATEY C, PALOMINO-MORALES R et al.: TNFA-308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2011; 216: 125-30.
18. DESSEIN P, SEMB AG: Could cardiovascular disease risk stratification and management in rheumatoid arthritis be enhanced?. Ann Rheum Dis 2013; 72: 1743-6.
19. SECCHIERO P, CANDIDO R, CORRALINI F et al.: Systemic TRAIL delivery shows anti-atherosclerotic activity in apoE-null diabetic mice. Circulation 2006; 114: 1522-30.
20. SECCHIERO P, CORRALINI F, CECONI C et al.: Potential prognostic significance of decreased serum TRAIL after myocardial infarction. PLoS ONE 2009; 4: e442.
21. OSMANCIK P, TERINGOVA E, TOUSEK P, PAULO P, WIDIMSKY P: Prognostic value of TNF-related apoptosis inducing ligand in acute coronary syndrome patients. PLoS ONE 2013; 8: e53860.
22. NIESSNER A, HOGENSINNER PJ, RYCHLI K et al.: Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J 2009; 30: 789-96.
23. ZIOLKOWSKA M, KUROWSKA M, RADZI-KOWSKA A et al.: High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand and their normalization alter anti-tumor necrosis factor a treatment. Artritis Rheum 2002; 46: 1744-53.
24. ZAULI G, CORRALINI F, BOSSI F et al.: Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 2007; 110: 536-43.
25. SANDBERG WJ, YNDESTAD A, OIE E et al.: Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006; 26: 857-63.
26. KIECHL S, SCHETT G, WENNING G et al.: Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-80.
27. DESSEIN PH, LOPEZ-MEJIAS R, GONZALEZ-JUANATEY C et al.: Independent relationship of osteoprotegerin concentrations with endothelial activation and carotid atherosclerosis in patients with severe rheumatoid arthritis. J Rheumatol 2014; 41: 429-36.
28. ASANUMA YF, SHIMADA YF, KOUZU N et al.: Serum osteoprotegerin concentration is associated with carotid atherosclerotic plaque in patients with rheumatoid arthritis. Mod Rheumatol 2013; 23: 269-75.
29. LOPEZ-MEJIAS R, UBILLA B, GENRE F et al.: Osteoprotegerin concentrations relate independently to established cardiovascular disease in rheumatoid arthritis. J Rheumatol 2015; 42: 39-45.
30. - mice. Diabetologia 2011; 54: 3157-67.
31. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
32. ALETAHA D, NEOGI T, SILMAN AJ et al.: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
33. PREVOO ML, van't HOF, KUPER HH, van LEEUWEN MA, van de PUTTE LB, van RIEL PL: Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
34. LEVEY AS, CORESH J, BALK E et al.: National Kidney Foundation: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-47.
35. HO KK, PINSKY JL, KANNEL WB, LEVY D: The epidemiology of heart failure: the Framingham Heart Study. J Am Coll Cardiol 1993; 22 (Suppl. A): 6A-13A.
36. YNDESTAD A, DAMAS JK, EIKEN HG et al.: Increased gene expression of tumor necrosis superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. Cardiovasc Res 2002; 54: 175-82.
37. SCHOPPET M, RUPPERT V, HOFBAUER LC et al.: TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in non-ischemic dilated cardiomyopathy. Biochem Biophys Res Commun 2005; 338: 1745-50.
38. SECCHIERO P, ZERBINATI C, RIMONDI E et al.: TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 2004; 61: 1965-74.
39. HOFBAUER LC, SCHOPPET M, CHRIST M, TEICHMANN J, LANGE U: Tumor necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. Rheumatology 2006; 45: 1218-22.
40. ZAI-XING Y, YAN L, HAO W, YE Z, CHANG L, REN-QIAN Z: Preliminary clinical assessment of the expression of TNF-related apoptosis-inducing ligand (TRAIL) in patients with ankylosing spondylitis. J Clin Lab Anal 2008; 22: 138-45.
41. MICHOWITZ Y, GOLDSTEIN E, ROTH A et al.: The involvement of tumor necrosis factor-related apoptosis-inducing ligand in atherosclerosis. J Am Coll Cardiol 2005; 45: 1018-24.
42. WATT V, CHAMBERLAIN J, STEINER T, FRANCIS S, CROSSMAN D: TRAIL attenuates the development of atherosclerosis in apolipoprotein deficient mice. Atherosclerosis 2011; 215: 348-54.
43. ZAULI G, MONASTA L, RIMONDI E, VECCHI BRUNATTI L, RODILLO O, RONFANI L: Circulating TRAIL shows a significant post-partum decline associated to stressful conditions. PLoS ONE 2011; 6: e27011.
44. SECCHIERO P, RIMONDI E, GRAZIA DI LASIO M et al.: C-reactive protein downregulates TRAIL expression in human peripheral monocytes via an Erg-1-dependent pathway. Clin Cancer Res 2013; 19: 1949-59.
45. CASTELLINO G, VORRALINI F, TROTTA F, SECCHIERO P: Is there any role for tumor necrosis factor related apoptosis inducing ligand-osteoprotegerin (TRAIL-OPG) interaction in rheumatoid arthritis?. Ann Rheum Dis 2006; 67: 1196-7.